Cantor Fitzgerald Has Positive View of VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Verve Therapeutics in a research note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will post earnings per share of ($2.16) for the year, up from their previous estimate of ($2.38). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.36. The company had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright raised their price objective on Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, April 14th. William Blair restated an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. Guggenheim raised their price objective on Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Canaccord Genuity Group raised their price objective on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Finally, Royal Bank of Canada reduced their target price on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Verve Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $25.75.

Verve Therapeutics Stock Down 0.5%

Shares of VERV stock traded down $0.02 during mid-day trading on Monday, hitting $4.36. 1,383,381 shares of the company's stock were exchanged, compared to its average volume of 1,859,907. Verve Therapeutics has a fifty-two week low of $2.86 and a fifty-two week high of $9.31. The stock has a 50-day simple moving average of $4.61 and a two-hundred day simple moving average of $5.81. The stock has a market cap of $388.66 million, a price-to-earnings ratio of -1.77 and a beta of 1.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in Verve Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock valued at $101,000 after acquiring an additional 1,676 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Verve Therapeutics by 1.9% during the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock worth $627,000 after purchasing an additional 2,093 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Verve Therapeutics by 15.8% during the fourth quarter. Arizona State Retirement System now owns 19,593 shares of the company's stock worth $111,000 after purchasing an additional 2,669 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in shares of Verve Therapeutics by 11.2% during the first quarter. DekaBank Deutsche Girozentrale now owns 26,690 shares of the company's stock worth $122,000 after purchasing an additional 2,690 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Verve Therapeutics by 5.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company's stock worth $313,000 after purchasing an additional 2,742 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company's stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.